Ivabradine Crescent

Ivabradine, the active ingredient in Ivabradine Crescent, is a If channel inhibitor presented as an oral tablet for oral use. It lowers heart rate and is used to manage chronic stable angina and heart failure with reduced ejection fraction in adults. GNH USA supplies Ivabradine Crescent as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine acts on the cardiac sinus node to reduce heart rate, benefiting conditions where excessive heart rate contributes to symptoms.

Chronic stable angina: reduces the frequency of angina attacks by lowering myocardial oxygen demand. Heart failure with reduced ejection fraction: improves exercise capacity and may reduce hospitalisations by controlling heart rate. Symptomatic tachycardia in angina patients: provides rate control when beta‑blockers are insufficient or not tolerated.

Common Side Effects: - Bradycardia: resting heart rate may fall below 50 bpm. - Luminous phenomena (phosphenes): transient visual flashes. - Headache: mild to moderate intensity. - Dizziness or vertigo. - Fatigue or asthenia. - Nausea.

Serious or Rare Side Effects: - Symptomatic severe bradycardia requiring medical attention. - Atrial fibrillation or other arrhythmias. - Visual disturbances such as blurred vision or retinal changes. - Hypotension with syncope. - Hepatic enzyme elevation. - Severe allergic reactions (rash, angioedema).

Before initiating therapy, clinicians should assess baseline heart rate and cardiac function.

Monitor heart rate: ensure resting rate is ≥60 bpm before starting. Avoid in severe hepatic impairment: contraindicated due to altered metabolism. Use caution with concomitant beta‑blockers: risk of excessive bradycardia. Do not combine with strong CYP3A4 inhibitors: may increase plasma concentrations. Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk. Store at ambient temperature: keep in original container, protect from moisture and light.

Ivabradine may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can markedly raise ivabradine levels. - Other bradycardic agents (high‑dose beta‑blockers, digoxin): may cause severe bradycardia. - Additional If channel inhibitors (e.g., ranolazine): additive heart‑rate reduction.

Moderate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may require dose adjustment. - QT‑prolonging drugs: monitor ECG for interval changes. - CYP3A4‑inducing agents (e.g., rifampicin): may reduce efficacy, consider alternative therapy.